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severe AS (AVAs 0.8 Cmz).Methods: AVAwas measured by Gorlin formula
at cardiac catheterization in 252 consecutive pts with AS (151 males, 101
females; aged 87A 11 y). FSVR was calculated by achocardiography in all
pts within 24 hours by a physician unaware of hemodynamic findings.
Resuk: mean values of AVA and FSVR were 0.89 + 0.27 and 0.48 +
0.30, respectively. An high Iinear correlation was found (r= 0.88, p < 0.001).
True positive were 184, falae pesitive 14, true negative 42, false negative
8 pts. Conclusion: FSVR s 0.6 allows identification of AVAs 0.8 cmz with
excellent sensitivity (97%), good positive and negative predictive accuracy
(93% and 89%), fairly good specificity (77%). FSVR maybe considered an
alternative to CE: whenever this is not technically feasible.
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El7114 PulmonaryVenousFlowVelocityMeasurementsfortheQuantitativeAssessmentof MitraiRegurgitation
C. Seiler, B.C. Aeechbacher, B. Meier. University Hoapita/, Cardiolcgyj Bern,
Swifzerf.snd
Pulmonaiy venous Doppler flow velocity recordings have been used for
qualitative but not forquantitetive assessment of the severity of mitral regur-
gitation (MR). Systolic flow revereal in a pulmona~ vein reflecta severe MR
in the absence of covariables influencing pulmonary vein flow. The purpose
of the present study was to test the hypothesis that the ratio betwean systolic
and diastolic pUk?IOnav venous flOW VSkCity tkIV3 integral (pv VTl*/VTl,j)
predicts quantitatively the severity of MR as assessed by regurgitant fraction
(RF) or regurgitant orifice area (RO). RO was calculated acccwding to the
proximal ~sovelocity @ace area method (PISA). RF wasdeterminedWw
=cho-Doppler-derived total and forward stroke volume (RFsrmdard), as weli
as echo-derived total stroke volume and PISA-derived regurgitant volume
(RFPISJ patients (pts) with atrial fibrillationlflutter, LV ejection fracrion s
45% and aortic regurgitation were not included in the study. Sixty pts (age =
81 yrs, blood pressure= 130/77 mmHg) with MR and RFPISA of O-W% were
examined. RFa,nti~ = 0.85 RFPISA + 5, r = 0.93, p = 0.0001.
10 r=o.aa,p=o.ccOl
Conclusions: (1)The ratio between systolic and diastolic pulmonary ve-
nous flowvelocity time integral allows quantitative assessment of the severity
of MR by regurgitant fraction. (2) Those measurements are accurate in pts
without covariables affecting pulmonary venous flow. (3) Quantitative pul-
monary venous flow velocity measurements cannot be uaad to differentiate
among minimal and moderate MR by regurgitant orifice area measurements.
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1711-5]siWlifiedcontinuitYaic@atiOnOfAOnicvaiva
AreaUsingContinuousWaveDopplerOnly:
Correctionfor3-DimenaionaiValveShape
J.-K. Song,D. Gilon, G.P. Foster, M.D. Handschumacher, E.G. Cape,
J. Solheim, R.A. Levine. Massachusetts Genersl Hospital, Boston, MA, USA
Clinical application of the mntinuity squation (CE) to calculate aortic valve
area is confounded by uncertainties regarding location of the pulsed Doppler
(PD) aample volume measuring subvalvular velocity at the annulus (van.),
and by arrhythmias that limit combining velocities (V’s) above and below
the valve from different beata. Recent work auggeats that both V’s might be
obtained in the same beat from the continuous wave Doppler (CW) trace that
frequently has a second lower velocity (Vl) reflecting subvalvular flow. To
determine whether VI by Coequals the required !/..” by PD, we compared
them in 2 settings: 6 aortic valve models derived from 3D reconstruction of
patients (pte)with flat ordoming stenoses and built bylaaerstereolithography;
and 18 pts with doming or very flat calcific valves (9 each).
DOMED cwDQ@f Ml
Results: Intheflatvalvea, the CWVl approximately equaled Van. (VINmn
= 1.06+ 0.15 in pts, 0.94 + 0.05 in models), suggesting that the subvahular
flow column that fills the beam width (producing an intenae VI) ends near the
annulus. In the doming valves, VI exceeded V~. (VI/V~n. = 1.43 + 0.18 in
pts, 1.47+ 0.16 in models, p= 0.001 vsflat), consistent with a fully insonated
subvalvular flow column that ends within the dome, where VI occurs by
PD. Calculating Van. as VI for flat valves and 0.7 x V1 for domes agreed
well within V.nn by PD. (mean error = 1.2 cmk, p > 0.85). Conclusion: The
CW double envelope with correction for valve shape can simplify clinical
application of the continuity equation technique for aortic stenosis,
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1711-6]lntra-oPe~ativeE~ho~ar~io~~aPhYin~efivent~i~uia~
RemodelingSurgery
G.M. Scelia, P.M. McCarthy, R.C. Starling, R.L. Vargo, T.M. Buda,
J.D. Thomas. C/eve/and Clinic Foundation, Cleveland, OH, USA
The left ventricular remodeling procedure (LVR) ie a radical surgicsl ap-
proach to congestive heart failure, with excision of the entire posterolateral
LV wall. Intraoparative echocardiography guides the excision, any related
mitral valvuloplasty and post-pump management. Resu/ts: 15 pts have un-
dergone LVR,age 34-66 (mean 50.2 yffi, 11male), exclusively for idiopathic
cardiomyopathy. LV end diastolic diametar (LVIDd) and volume (LVEDV)
decreased markedly. Stroke voluma (SV), via outflow tract pulsed Doppler,
increased as did Forward EF (SV*100?Le/LVEDV).The inter-papillary distance
(IPD), which outlinea the excised segment accurately predicted LVIDdP~~.w
(via LVIDdP,~w – IPD/z). Predicted LVIDdPo,tW6.2 + 1.0 cm, actual 6.0 +
0.6 cm (r = 0.75).
n=15 Pre-00 pOSt-OD D
LVEDV (ml) 236 +S0 107+39 <0.00001
LVIDd(cm) so* 1.1 6,0 + 0.6 <0.00001
SV (mlj ‘ 32+ 9 36& 7 0.03
ForwardEF (“A) 15.S +6,9 36.5+ 10.7 <0.00001
Mitral Regurg. 2.5+ O+-Trivial
IPD
<0.00001
5.6 k 1.2 -=2
Conclusions: Intra-oparetive achocardiography demonstrates a signifi-
cant improvement in LV dimensions and function during left ventricular re.
mcdeling surgety forcongastive heart failure, and helps guida the myocardial
resection and mitral valvuloplasfy.
El712 Basic Pharmacology of Platelets, Thrombosis,
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[712.1 I An AntiPia~~ietDru~, ~i~ioPi~ine,,nhibi*
Haparin-inducedThrombocytopsnia(HiT)
Responsesas MeaeuredbyPiateletAggregometry
and“C SarotoninReleaae
J. Faread, W. Jeske, J.M. Walenga, L. Yang, M. Ero, B. Lewis. Loyo/a
University Medics/ Centec Maywood, IL, USA
Heparin-induced thrombocyfopenia remains a catastrophic syndrome with
both acomplicatad diagnosis and poerprognosis. While substitute antithrom-
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a GPllb/lHa Receptor Antagonist, in the Conscious
Dog
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El7123 Low-Shear Platelet Adhesion is Inhibited by GPllb/fila Antagonist DMP-728
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Postmyocardial Infarction Stage
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Potent Approech to Inhibit Human Smooth Muscle
Cell Growth
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